Sigvotatug Vedotin

3 trials 1 recruiting

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

1 Recruiting

1 Completed trials

2 Sponsors

16 Countries

Phase III

Phase I/II

Phase III: 2 Phase I/II: 1

Oversight events:

1 serious breach 1 corrective measure across 1 trial

View oversight register →

Indications tested

Non-small cell lung cancer 2 Non-small cell lung cancer metastatic 1

Sponsors using this IMP

Pfizer Inc. 2 Seagen Inc. 1

All trials

3 total

A Study to Learn about the Study Medicine called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers Pending

2025-523526-40-00 Phase I/II 4 countries Pfizer Inc.
A Study to Learn About the Study Medicine Called Sigvotatug Vedotin in People with Locally Advanced, Unresectable, or Metastatic Non-Small C… Recruiting

2024-517968-36-00 Phase III 15 countries Pfizer Inc.
A study of sigvotatug vedotin versus docetaxel in previously treated non-small cell lung cancer (Be6A Lung-01) Ended

2023-503827-25-01 Phase III 13 countries Seagen Inc.

Showing 1–3 of 3 trials

← All drugs A–Z